{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T18:51:39Z","timestamp":1775155899562,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005410","name":"American-Italian Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.esmoop.2022.100428","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T17:57:30Z","timestamp":1646675850000},"page":"100428","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?"],"prefix":"10.1016","volume":"7","author":[{"given":"S.","family":"Morganti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Bianchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9064-0113","authenticated-orcid":false,"given":"C.","family":"Criscitiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2022.100428_bib1","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100428_bib2","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100428_bib3","first-page":"S5","volume":"94","author":"Slamon","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2022.100428_bib4","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.20.01204","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years\u2019 follow-up","volume":"39","author":"Piccart","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100428_bib5","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)61094-6","article-title":"2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial","volume":"382","author":"Goldhirsch","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100428_bib6","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1016\/S0140-6736(19)30650-6","article-title":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial","volume":"393","author":"Earl","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100428_bib7","doi-asserted-by":"crossref","first-page":"S1283","DOI":"10.1016\/j.annonc.2021.08.2083","article-title":"Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer","volume":"32","author":"Earl","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100428_bib8","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1200\/JCO.2008.21.4577","article-title":"Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial","volume":"27","author":"Joensuu","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100428_bib9","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1093\/annonc\/mdy414","article-title":"Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study","volume":"29","author":"Conte","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100428_bib10","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1001\/jamaoncol.2018.1380","article-title":"Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: the SOLD randomized clinical trial","volume":"4","author":"Joensuu","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2022.100428_bib11","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/annonc\/mdv213","article-title":"Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)","volume":"26","author":"Mavroudis","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100428_bib12","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1016\/S0140-6736(19)30653-1","article-title":"6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial","volume":"393","author":"Pivot","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100428_bib13","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100428_bib14","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","article-title":"Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 - positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831","volume":"32","author":"Perez","year":"2014","journal-title":"J.\u00a0Clin. Oncol"},{"key":"10.1016\/j.esmoop.2022.100428_bib15","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/annonc\/mdu177","article-title":"Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial","volume":"25","author":"Kramar","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100428_bib16","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100428_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.101965","article-title":"HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis","volume":"84","author":"Schettini","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2022.100428_bib18","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/S1470-2045(20)30450-2","article-title":"A\u00a0multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation","volume":"21","author":"Prat","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100428_bib19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1406281","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer","volume":"372","author":"Tolaney","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100428_bib20","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1200\/JCO.20.03398","article-title":"Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial","volume":"39","author":"Tolaney","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100428_bib21","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.ejca.2015.05.028","article-title":"Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study","volume":"51","author":"Pivot","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2022.100428_bib22","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1038\/bjc.2016.357","article-title":"Trastuzumab-associated cardiac events in the Persephone trial","volume":"115","author":"Earl","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2022.100428_bib23","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/annonc\/mdx494","volume":"28","author":"Nitz","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100428_bib24","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S1470-2045(21)00122-4","article-title":"Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial","volume":"22","author":"P\u00e9rez-Garc\u00eda","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100428_bib25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JGO.19.00293","article-title":"Cost effectiveness of trastuzumab for management of breast cancer in India","volume":"6","author":"Gupta","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.esmoop.2022.100428_bib26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12962-019-0174-7","article-title":"Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer","volume":"17","author":"Gershon","year":"2019","journal-title":"Cost Eff Resour Alloc"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922000497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922000497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:25:52Z","timestamp":1761855952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922000497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S2059702922000497"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100428","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100428","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100428"}}